StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
OTX.SI$0.25+0.00%
Fair $0.25+0.0%

OTX.SI

Medinex Limited

Healthcare / Medical Care FacilitiesSES

$0.25

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.25Fund rank 39/100 · Data gapFallback financials|
SA 59/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $2.7M · quality 85.7/100

Data gap 39/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 87/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

59/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · OTX.SILocal privado en este navegador · Medinex Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$34M

P/E

12.5x

↓

EV/EBITDA

10.3x

↓

ROE

13.5%

↑

Gross Margin

80.2%

↑

Debt/Equity

0.06

↓
52-Week Range$0
$0$0

TradingView lightweight chart

OTX.SI price, volumen y niveles de valoración

Último $0.250Periodo -10.7%
Fair value: $0.250

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

-1.4%

FCF CAGR

-3.5%

FCF margin

20.5%

FCF / Net income

1.15x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $12.4M · net income $2.2M · FCF $2.5M

2023-FY → 2026-FY

Gross margin

80.2%+7.1% pts

Operating margin

33.3%+3.9% pts

Net margin

17.9%+4.8% pts

FCF margin

20.5%-1.3% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$12.4M$12.4M$12.8M$12.6M$13.0M
Net Income$2.2M$2.2M$2.8M$1.0M$1.7M
EBITDA$3.0M$3.0M$3.6M$1.8M$2.9M
EPS0.020.020.020.010.01
Gross Margin80.2%80.2%77.5%76.9%73.1%
Operating Margin33.3%33.3%32.8%30.2%29.4%
Net Margin17.9%17.9%22.1%8.2%13.1%
Balance Sheet
Debt/Equity0.060.060.100.130.13
Current Ratio3.503.50———
Cash Flow
Free Cash Flow$2.5M$2.5M$3.3M$2.7M$2.8M
Returns
ROE13.5%13.5%16.9%6.4%9.7%
Valuation
P/E12.5012.509.2524.4215.48
EV/EBITDA10.2810.286.8113.538.68
P/B2.022.021.571.571.50
Growth & Yield
Revenue Growth-3.1%-3.1%1.8%-2.9%—
EPS Growth-22.0%-22.0%177.9%-38.9%—
Dividend Yield6.7%6.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

9.9%

razonable

EPS terminal req.

$0.02

Spread vs growth

-31.9%

5Y implied EPS CAGR

10.0%

razonable

EPS terminal req.

$0.03

Spread vs growth

-31.9%

10Y implied EPS CAGR

10.0%

razonable

EPS terminal req.

$0.04

Spread vs growth

-31.9%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +31.7%

Total return

+31.7%

Start / end P/E

9.3x → 15.0x

EPS bridge

0.02 → 0.02

Residual

-13.2%

EPS growth-22.0%
Multiple rerating+60.2%
Dividend+6.7%
Residual / FX / buybacks / cross-term-13.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.